Compare PHAR & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHAR | HELP |
|---|---|---|
| Founded | 1988 | N/A |
| Country | Netherlands | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 793.4M | 889.9M |
| IPO Year | 2020 | 2020 |
| Metric | PHAR | HELP |
|---|---|---|
| Price | $10.16 | $12.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $38.33 | ★ $51.50 |
| AVG Volume (30 Days) | 33.8K | ★ 1.7M |
| Earning Date | 05-07-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.04 | N/A |
| Revenue Next Year | $2.51 | N/A |
| P/E Ratio | $3,041.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.62 | $3.76 |
| 52 Week High | $21.34 | $15.15 |
| Indicator | PHAR | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 38.04 | 52.20 |
| Support Level | $9.62 | $11.68 |
| Resistance Level | $11.60 | $14.75 |
| Average True Range (ATR) | 0.47 | 0.96 |
| MACD | -0.03 | -0.20 |
| Stochastic Oscillator | 9.45 | 22.04 |
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.